Syenza News — health technology assessment, market access and health economics
Hybrid healthcare hub in Portugal: ULSSM, Medtronic join forces
The Santa Maria Local Health Unit and Medtronic have signed a memorandum to create a hybrid care model that pairs in-person care with remote monitoring. Four clinical areas come first. #SyenzaNews #HealthcareInnovation #DigitalHealth
Recent Posts
Retatrutide Head-to-Head Trial Shows Greater A1C Cut Than Ozempic
Oct 29
Portugal Outpatient Medicine Spend Rises 7.9%, Led by Diabetes Drugs
Oct 29
Orphan Medical Devices Pilot Closes With 13 Positive Status Opinions
Oct 28
EMA Expert Panel Advice Pilot Ends With a Streamlined 60-Day Procedure
Oct 28
Individualised gene therapies for rare diseases: FDA draft guidance
Oct 28Syenza's Top Picks
Adverse reaction reports in Portugal rise with GLP-1 use
Oct 19, 2026
Palbociclib Maintenance in HER2-Positive Breast Cancer: EMA Withdrawal
Oct 23, 2026
Health Economists in Clinical Trials: Why Early Engagement Matters
Oct 22, 2026
New Drug Launch Prices Stay High While Patients Wait for Access
Oct 21, 2026
CagriSema Weight Loss in Women: Menopause Stages in REDEFINE 1
Oct 21, 2026
Medicaid Provider Taxes Raise Private Insurance Premiums, ASPE Finds
Oct 21, 2026
Latest News
Clinical Practice
KRAS G12C inhibitor divarasib outperforms approved drugs
The KRAS G12C inhibitor divarasib improved survival versus sotorasib or adagrasib in the phase III Krascendo 1 trial. #SyenzaNews #oncology #NSCLC
Europe
Novartis core operating income rises, 2026 outlook raised
Novartis core operating income rose 10% at constant exchange rates in Q3 2026, and 2026 guidance for the measure was raised. #SyenzaNews #MarketAccess
Clinical Practice
Izalontamab brengitecan breast cancer: 59% lower risk of progression
Phase 3 PANKU-Breast01 data show izalontamab brengitecan cut the risk of disease progression or death by 59% versus chemotherapy in HR-positive, HER2-negative breast cancer. #SyenzaNews #breastcancer #oncology
Clinical Practice
Keytruda Monotherapy Endometrial Cancer: 43% Risk Reduction
Keytruda monotherapy cut the risk of progression or death by 43% against platinum chemotherapy in dMMR endometrial cancer, in the KEYNOTE-C93 Phase 3 trial. #SyenzaNews #oncology #precisionmedicine #endometrialcancer
Europe
Endometriosis and fibroid tablets in England: prescriptions soar
NHS use of NICE-recommended endometriosis and fibroid tablets in England more than tripled in a year, from 1.2 million to 3.7 million tablets. #SyenzaNews #MarketAccess
Clinical Practice
JNJ-6143 prostate cancer: 75% tumor response in Phase 1 trial
JNJ-6143, an investigational first-in-class oral molecule, produced a 75% tumor response rate among patients with measurable disease in a Phase 1 study. #SyenzaNews #prostatecancer #oncology
Clinical Practice
Claudin 18.2 antibody-drug conjugate prolongs survival in gastro-oesophageal cancer
Sone-Ve doubled median overall survival versus investigator’s choice in third-line and later gastro-oesophageal cancer; second-line PFS missed significance.
Diseases
Obesity drug reimbursement in Portugal: new SNS terms
Portaria n.º 464/2026/1 limits state reimbursement for obesity medicines to SNS patients in a hospital obesity pathway. Cover is 15% for 12 months. #SyenzaNews #MarketAccess
Diseases Free account
Antiretroviral Tender Awards Declared Invalid by Pretoria Court
A Pretoria court has declared invalid the antiretroviral tender awards for two items and ordered the health department to redo the split within 120 days. Cipla’s review succeeded on all five grounds, while Hetero’s challenge was dismissed with attorney-and-client costs. #SyenzaNews #SouthAfrica #HIV
Clinical Practice
Intismeran Adjuvant Melanoma Trial Cuts Recurrence Risk by 42%
Merck and Moderna report a 42% reduction in recurrence or death for intismeran plus KEYTRUDA in resected stage IIB-IV melanoma, with full data at ESMO 2026. #SyenzaNews #melanoma #MarketAccess
Value Science Weekly
The week in health technology assessment, market access and health economics — what moved, and what it means.
